DB
ANTX icon

Dmitry Balyasny’s AN2 Therapeutics ANTX Stock Holding History

Dmitry Balyasny’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Buy
+556,027
New +$2.39M ﹤0.01% 1669
2024
Q1 		– Sell
-19,285
Closed -$395K – 2589
2023
Q4 		$395K Buy
+19,285
New +$323K ﹤0.01% 2049

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Dmitry Balyasny's ANTX Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 556,027 shares worth $2.69M. The stake represents ﹤0.01% of the portfolio and ranks #1669 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in ANTX as recently as Q4 2023.

Dmitry Balyasny first reported a position in ANTX in Q4 2023 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Dmitry Balyasny held 556,027 shares of AN2 Therapeutics worth $2.69M as of Q2 2026.
  • AN2 Therapeutics was a new Dmitry Balyasny position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1669 holding.
  • Dmitry Balyasny first reported a position in AN2 Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.